Alembic Pharmaceuticals’ arm gets USFDA’s final approval for Docosanol Cream

04 May 2022 Evaluate

Alembic Pharmaceuticals’ wholly owned subsidiary -- Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Docosanol Cream, 10% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Abreva Cream, 10% (OTC), of GlaxoSmithKline Consumer Healthcare. Docosanol Cream, 10% (OTC) is used for cold sore/fever blisters on the face or lips.

Docosanol Cream, 10% (OTC) has an estimated market size of $60 million for twelve months ending December 2021 according to IQVIA. Alembic has received a cumulative total of 166 ANDA approvals (142 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

837.80 -14.50 (-1.70%)
29-Dec-2025 14:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.00
Dr. Reddys Lab 1266.30
Cipla 1496.65
Zydus Lifesciences 906.20
Lupin 2084.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×